This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Douglas, C. M.
Right arrow Articles by Kurtz, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douglas, C. M.
Right arrow Articles by Kurtz, M. B.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., 11 1997, 2471-2479, Vol 41, No. 11
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

CM Douglas, JA D'Ippolito, GJ Shei, M Meinz, J Onishi, JA Marrinan, W Li, GK Abruzzo, A Flattery, K Bartizal, A Mitchell and MB Kurtz
Department of Biochemistry, Merck Research Laboratories, Rahway, New Jersey 07065, USA.

Pneumocandins and echinocandins are fungicidal antibiotics, currently in clinical development, that inhibit 1,3-beta-D-glucan synthase (GS) in several human fungal pathogens. We have identified a gene from the diploid organism Candida albicans that encodes a target of these inhibitors. A 2.1-kb portion of this gene, designated CaFKS1, has significant homology to the Saccharomyces cerevisiae FKS1 and FKS2 genes, which encode partially functionally redundant subunits of GS. To evaluate the role of CaFkslp in susceptibility to echinocandins, we disrupted CaFKS1 on one homolog each of the spontaneous pneumocandin- resistant C. albicans mutants CAI4R1, NR2, NR3, and NR4. These mutants had been selected previously on agar plates containing the pneumocandin L-733,560. The clones derived from this transformation were either resistant (Ech[r]) or fully sensitive (Ech[s]) to inhibition by L- 733,560 in both liquid broth microdilution and in vitro GS assays. The site of plasmid insertion in the transformants was mapped by Southern blot analysis, using restriction site polymorphisms in the CaFKS1 gene to distinguish between the two alleles (designated CaFKS1h and CaFKS1b). For strains CAI4R1 and NR2, the CaFKS1b allele was disrupted in each Ech(r) transformant; for strain NR4, CaFKS1h was disrupted in each Ech(r) transformant. We conclude that (i) strains CAI4R1, NR2, and NR4 are heterozygous for a dominant or semidominant pneumocandin resistance mutation at CaFKS1, (ii) drug resistance mutations can occur in either CaFKS1 allele, and (iii) CaFks1p is a target of the echinocandins. For transformants of strain NR3, all the clones we analyzed were uniformly Ech(r), and only the CaFKS1h allele, either in disrupted or wild-type form, was detected on genomic Southern blots. We believe gene conversion at the CaFKS1 locus may have produced two Cafks1h alleles that each contain an Ech(r) mutation. Transformants derived from the mutants were analyzed for susceptibility to pneumocandin treatment in a mouse model of disseminated candidiasis. Strains heterozygous for the resistant allele (i.e., C. albicans CAI4R1, NR2, and NR4) were moderately resistant to treatment, while strains without a functional Ech(s) allele (i.e., strain NR3 and derivatives of strain CAI4R1 with the disruption plasmid integrated in the Ech[s] allele) displayed strong in vivo echinocandin resistance. Finally, we were unable to inactivate both alleles at CaFKS1 by two- step integrative disruption, suggesting that CaFks1p is likely to be an essential protein in C. albicans.


This article has been cited by other articles:

  • Thompson, G. R. III, Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S. II, Patterson, T. F. (2008). Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection. Antimicrob. Agents Chemother. 52: 3783-3785 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., Dannaoui, E. (2008). Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3092-3098 [Abstract] [Full Text]  
  • Richards, T. S., Oliver, B. G., White, T. C. (2008). Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J Antimicrob Chemother 62: 349-355 [Abstract] [Full Text]  
  • Krysan, D. J., Didone, L. (2008). A High-Throughput Screening Assay for Small Molecules That Disrupt Yeast Cell Integrity. J Biomol Screen 13: 657-664 [Abstract]  
  • Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., Perlin, D. S. (2008). A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility. Antimicrob. Agents Chemother. 52: 2305-2312 [Abstract] [Full Text]  
  • Cowen, L. E., Steinbach, W. J. (2008). Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot Cell 7: 747-764 [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2008). In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J. Clin. Microbiol. 46: 150-156 [Abstract] [Full Text]  
  • Rocha, E. M. F., Garcia-Effron, G., Park, S., Perlin, D. S. (2007). A Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51: 4174-4176 [Abstract] [Full Text]  
  • Jacobsen, M. D., Whyte, J. A., Odds, F. C. (2007). Candida albicans and Candida dubliniensis Respond Differently to Echinocandin Antifungal Agents In Vitro. Antimicrob. Agents Chemother. 51: 1882-1884 [Abstract] [Full Text]  
  • Bowman, J. C., Abruzzo, G. K., Flattery, A. M., Gill, C. J., Hickey, E. J., Hsu, M. J., Nielsen Kahn, J., Liberator, P. A., Misura, A. S., Pelak, B. A., Wang, T. C., Douglas, C. M. (2006). Efficacy of Caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob. Agents Chemother. 50: 4202-4205 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., Scalise, G. (2006). Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis.. Antimicrob. Agents Chemother. 50: 2719-2727 [Abstract] [Full Text]  
  • Hakki, M., Staab, J. F., Marr, K. A. (2006). Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy.. Antimicrob. Agents Chemother. 50: 2522-2524 [Abstract] [Full Text]  
  • Ha, Y.-s., Covert, S. F., Momany, M. (2006). FsFKS1, the 1,3-{beta}-Glucan Synthase from the Caspofungin-Resistant Fungus Fusarium solani.. Eukaryot Cell 5: 1036-1042 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance.. J. Clin. Microbiol. 44: 760-763 [Abstract] [Full Text]  
  • Kartsonis, N., Killar, J., Mixson, L., Hoe, C.-M., Sable, C., Bartizal, K., Motyl, M. (2005). Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome. Antimicrob. Agents Chemother. 49: 3616-3623 [Abstract] [Full Text]  
  • Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S. A., Kurtz, M., Teppler, H., Douglas, C. M., Perlin, D. S. (2005). Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 49: 3264-3273 [Abstract] [Full Text]  
  • Flaherty, P., Giaever, G., Kumm, J., Jordan, M. I., Arkin, A. P. (2005). A latent variable model for chemogenomic profiling. Bioinformatics 21: 3286-3293 [Abstract] [Full Text]  
  • Canton, E., Peman, J., Gobernado, M., Alvarez, E., Baquero, F., Cisterna, R., Gil, J., Martin-Mazuelos, E., Rubio, C., Sanchez-Sousa, A., Serrano, C. (2005). Sensititre YeastOne Caspofungin Susceptibility Testing of Candida Clinical Isolates: Correlation with Results of NCCLS M27-A2 Multicenter Study. Antimicrob. Agents Chemother. 49: 1604-1607 [Abstract] [Full Text]  
  • Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E. Jr., Douglas, C. M. (2005). Caspofungin Inhibits Rhizopus oryzae 1,3-{beta}-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. Antimicrob. Agents Chemother. 49: 721-727 [Abstract] [Full Text]  
  • Kellner, E. M., Orsborn, K. I., Siegel, E. M., Mandel, M. A., Orbach, M. J., Galgiani, J. N. (2005). Coccidioides posadasii Contains a Single 1,3-{beta}-Glucan Synthase Gene That Appears To Be Essential for Growth. Eukaryot Cell 4: 111-120 [Abstract] [Full Text]  
  • Odds, F. C., Motyl, M., Andrade, R., Bille, J., Canton, E., Cuenca-Estrella, M., Davidson, A., Durussel, C., Ellis, D., Foraker, E., Fothergill, A. W., Ghannoum, M. A., Giacobbe, R. A., Gobernado, M., Handke, R., Laverdiere, M., Lee-Yang, W., Merz, W. G., Ostrosky-Zeichner, L., Peman, J., Perea, S., Perfect, J. R., Pfaller, M. A., Proia, L., Rex, J. H., Rinaldi, M. G., Rodriguez-Tudela, J.-L., Schell, W. A., Shields, C., Sutton, D. A., Verweij, P. E., Warnock, D. W. (2004). Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. J. Clin. Microbiol. 42: 3475-3482 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2004). Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical Isolates. J. Clin. Microbiol. 42: 3117-3119 [Abstract] [Full Text]  
  • Hernandez, S., Lopez-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., Graybill, J. R. (2004). Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis. Antimicrob. Agents Chemother. 48: 1382-1383 [Abstract] [Full Text]  
  • Imhof, A., Balajee, S. A., Marr, K. A. (2003). New Methods To Assess Susceptibilities of Aspergillus Isolates to Caspofungin. J. Clin. Microbiol. 41: 5683-5688 [Abstract] [Full Text]  
  • Tavanti, A., Gow, N. A. R., Senesi, S., Maiden, M. C. J., Odds, F. C. (2003). Optimization and Validation of Multilocus Sequence Typing for Candida albicans. J. Clin. Microbiol. 41: 3765-3776 [Abstract] [Full Text]  
  • Bartizal, C., Odds, F. C. (2003). Influences of Methodological Variables on Susceptibility Testing of Caspofungin against Candida Species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47: 2100-2107 [Abstract] [Full Text]  
  • Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., Conklin, R. (2003). In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model. Antimicrob. Agents Chemother. 47: 1187-1192 [Abstract] [Full Text]  
  • Letscher-Bru, V., Herbrecht, R. (2003). Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51: 513-521 [Abstract] [Full Text]  
  • Davis, D. A., Bruno, V. M., Loza, L., Filler, S. G., Mitchell, A. P. (2002). Candida albicans Mds3p, a Conserved Regulator of pH Responses and Virulence Identified Through Insertional Mutagenesis. Genetics 162: 1573-1581 [Abstract] [Full Text]  
  • Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., Lopez-Ribot, J. L. (2002). In Vitro Activity of Caspofungin against Candida albicans Biofilms. Antimicrob. Agents Chemother. 46: 3591-3596 [Abstract] [Full Text]  
  • Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., Douglas, C. M. (2002). The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro. Antimicrob. Agents Chemother. 46: 3001-3012 [Abstract] [Full Text]  
  • Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., Heitman, J. (2001). Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR. Antimicrob. Agents Chemother. 45: 3162-3170 [Abstract] [Full Text]  
  • Weig, M., Haynes, K., Rogers, T. R., Kurzai, O., Frosch, M., Muhlschlegel, F. A. (2001). A GAS-like gene family in the pathogenic fungus Candida glabrata. Microbiology 147: 2007-2019 [Abstract] [Full Text]  
  • Enloe, B., Diamond, A., Mitchell, A. P. (2000). A Single-Transformation Gene Function Test in Diploid Candida albicans. J. Bacteriol. 182: 5730-5736 [Abstract] [Full Text]  
  • Del Poeta, M., Cruz, M. C., Cardenas, M. E., Perfect, J. R., Heitman, J. (2000). Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 739-746 [Abstract] [Full Text]  
  • Onishi, J., Meinz, M., Thompson, J., Curotto, J., Dreikorn, S., Rosenbach, M., Douglas, C., Abruzzo, G., Flattery, A., Kong, L., Cabello, A., Vicente, F., Pelaez, F., Diez, M. T., Martin, I., Bills, G., Giacobbe, R., Dombrowski, A., Schwartz, R., Morris, S., Harris, G., Tsipouras, A., Wilson, K., Kurtz, M. B. (2000). Discovery of Novel Antifungal (1,3)-beta -D-Glucan Synthase Inhibitors. Antimicrob. Agents Chemother. 44: 368-377 [Abstract] [Full Text]  
  • Thompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., Kurtz, M. (1999). A Glucan Synthase FKS1 Homolog in Cryptococcus neoformans Is Single Copy and Encodes an Essential Function. J. Bacteriol. 181: 444-453 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»